Why Adherium (ASX:ADR) remains reliant on shareholder loans as its US remote patient monitoring business scales

Sonal Goyal

16 October 2026 11:02 PM AEDT

Why Adherium (ASX:ADR) remains reliant on shareholder loans as its US remote patient monitoring business scales

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Adherium's FY2026 Revenue rose 157 per cent to A$2.10 million, while its net loss grew to A$14.16 million.
Cash was about A$1.38 million at 30 June 2026, and the company's own runway estimate was 0.35 of a quarter.
On 16 September 2026 Trudell loans were consolidated into a single unsecured term Loan of A$4,671,025 at 12 per cent a year, repayable by 31 August 2027.

Adherium (ASX:ADR) is a Melbourne-based digital respiratory health company whose Hailie platform combines connected inhaler sensors with software that monitors medication adherence. Revenue is growing from a low base, but the company continues to fund its operations with loans from its largest shareholder, Trudell Medical, and from a newer lender, Barvest Ventures. That funding structure shapes its risk profile as much as the technology does.

Business and stage

Adherium sells FDA-cleared Smartinhaler devices and the Hailie app, and increasingly offers a US remote patient monitoring (RPM) service under which clinicians bill for monitoring patients. Its FY2026 preliminary results, released on 31 August 2026, showed revenue up 157 per cent to A$2.10 million, while the net loss widened to A$14.16 million. The operating cash outflow of A$14.83 million was largely covered by A$14.95 million raised through share issues. The Business is commercial but not yet self-funding.

Recent developments

The June 2026 quarterly report, released on 29 July 2026, showed cash of about A$1.38 million, down from A$2.96 million at 31 March. The operating outflow for the quarter was A$3.91 million against customer receipts of A$408,000, and the company's own runway estimate was 0.35 of a quarter. Recurring RPM subscription revenue reached A$479,000, up 39 per cent on the March quarter. Cumulative device shipments stood at 5,302 and activations at 3,831, against a target of about 10,000 shipments by 31 December 2026.

Shareholders approved a 100-for-1 share consolidation at the extraordinary general meeting on 19 June, and the company confirmed its completion on 7 July 2026. Leadership has also changed: on 29 July 2026 Adherium announced that CEO Dawn Bitz was stepping down, with Chief Commercial Officer John Perry appointed interim CEO, and Brad Wilson was named chief financial officer on 12 October 2026.

Loans and dilution risk

The company has borrowed repeatedly, and in rising amounts. Trudell provided a US$1.65 million short-term loan on 29 June 2026, followed by an A$1 million Facility announced on 18 August. On 16 September 2026, these amounts, a further A$1.3 million and accrued interest were consolidated into a single unsecured term loan of A$4,671,025 at 12 per cent a year, capitalised monthly and repayable by 31 August 2027. On 6 October 2026, Adherium added an A$700,000 Unsecured Loan from Barvest Ventures, a company related to Trudell, at the same 12 per cent rate and due on 30 September 2027. The board said third-party funding Options were limited, uncertain or less favourable, and that the loans avoid immediate dilution.

In the preliminary results, the directors consider the going-concern basis appropriate but note that the auditor's report may include a material uncertainty emphasis. Equity stood at a Deficit of A$1.29 million at 30 June 2026. Debt compounding at 12 per cent, together with further funding needs, creates a risk of an equity raising or debt conversion that would dilute holders, although none has been announced.

Sector context and risks

The RPM model depends on US reimbursement rules. The Annual Report notes that new CPT codes introduced from 1 January 2026 reduced certain billing, and proposed changes to Medicare payment rules for 2027 are not yet final. Other risks include leadership turnover and competition from other digital health providers. Interim results from the Intermountain Health iCARE study, presented in May 2026, reported a 57 per cent lower total cost of care per patient, although interim findings do not by themselves secure contracts.

What's Next

The annual report was lodged on 30 September 2026, and the company expected a study receipt of A$264,000 related to AstraZeneca in the September quarter. Progress towards the target of about 10,000 device shipments by 31 December 2026, and the 2027 repayment dates on the Trudell and Barvest loans, are the other markers to follow.

FAQs

Q:What does Adherium do?

A:Adherium sells FDA-cleared Smartinhaler devices and the Hailie app, which pair connected inhaler sensors with adherence-monitoring software, and increasingly provides a US remote patient monitoring service.

Q:How is Adherium funding its operations?

A:Recently through loans: a consolidated A$4,671,025 unsecured term loan from Trudell Medical at 12 per cent a year, repayable by 31 August 2027, and an A$700,000 unsecured loan from Barvest Ventures due 30 September 2027.

Q:What were Adherium's FY2026 results?

A:Revenue rose 157 per cent to A$2.10 million, the net loss grew to A$14.16 million, and operating cash outflow was A$14.83 million. Equity was a deficit of A$1.29 million at 30 June 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.